Oral Cancer News

Grateful Dead guitarist plays concerts with tribute band to benefit the Oral Cancer Foundation

Source: truebluetribune.com Author: staff Mark Karan, former lead guitarist for the post Grateful Dead band, The Other Ones, and Joe Pulitano, drummer for the Grateful Dead tribute band, Deadbeat, who are both stage IV oral cancer survivors, recently teamed up to play three benefit concerts in the North East to raise money for the Oral Cancer Foundation and the Dana Farber Cancer Institute. Following Deadbeat’s benefit performances this spring, with Mark playing guest guitar, the two men donated $7,500 of the concert proceeds to the Oral Cancer Foundation to support the organization’s research, advocacy, and educational efforts. What’s interesting is how these two talented musicians, who did not know each other before their individual encounters with this deadly disease, came together. Like many who find themselves dealing with oral cancer, Joe had complained for 14 months to his doctor about voice change, shortness of breath when speaking, and a sore throat. He was eventually diagnosed with stage IV head and neck cancer. Years before Mark’s diagnosis with oral cancer, and after Jerry Garcia’s death, he was chosen to share his lead guitar slot with Steve Kimock in the Other Ones. Just two years ago, while laying in a hospital bed, Mark asked his wife to hand him his guitar and a piece of paper. Twenty minutes later, “Walk Through Fire” was written, a song about his personal resolve, humility, acceptance, courage and lessons learned in his brush with the life-threatening disease. “It was one of those songs you hope for, [...]

Oral Cancer Foundation News Team - A2014-06-17T18:55:31-07:00June, 2014|OCF In The News, Oral Cancer News|

The Eighth Annual Oral Cancer Walk for Awareness of New York at NYU raises more than $50,000

Source: dental.nyu.eduAuthor: Staff On Sunday, April 21, 2013, oral cancer survivors and their families joined dental students from the NYU chapter of the Student National Dental Association (SNDA), residents, dental hygiene students, nursing students, faculty, and staff from the NYU Colleges of Dentistry and Nursing for the eighth annual NYC Oral Cancer Awareness Walk, which set out from the Kissena Park Velodrome in Queens for a four-mile walk, ending at Citi Field, home of the Mets. The event attracted 600-plus walkers and raised over $50,000 -- the highest total to date – for oral cancer awareness, prevention, and treatment. In addition to NYUCD and NYUCN, sponsors included Bronx-Lebanon Hospital Center, the NYU Oral Cancer Center, Columbia University College of Dental Medicine, the Oral Cancer Foundation, New York Hospital in Queens, the Oral Cancer Consortium, the State University of New York at Stony Brook, the UMDNJ New Jersey Dental School, and Boulevard Dental Center. Free oral cancer screenings were available throughout the event. A highlight of the event was remarks by U.S. Representative Grace Meng (D-Queens), whose husband is Dr. Wayne Kye, ’02, clinical assistant professor of periodontology and implant dentistry. As he has done since 2006, Dr. Ross Kerr, clinical professor of oral and maxillofacial pathology, radiology and medicine, provided invaluable strategic advice, encouragement, and support to the extraordinary student volunteers who made the walk such a great success. *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2014-06-06T11:14:32-07:00June, 2014|OCF In The News, Oral Cancer News|

CDC reveals no drop in smokeless tobacco use among U.S. workers

Source: philly.comAuthor: Margaret Steele, HealthDay Reporter THURSDAY, June 5, 2014 (HealthDay News) -- Cigarette smoking continues to decline among Americans who work, but use of smokeless tobacco -- a known cause of cancer -- has held steady since 2005, U.S. health officials reported Thursday. Certain types of jobs -- construction and mining, especially -- are hotbeds of smokeless tobacco use, according to a study conducted by the U.S. National Institute for Occupational Safety and Health. Looking at tobacco use over five years, the researchers found a decline in cigarette smoking among working adults -- from about 22 percent in 2005 to 19 percent in 2010. But use of smokeless tobacco products such as chewing tobacco and snuff inched up slightly -- from 2.7 percent in 2005 to 3 percent in 2010."These findings can help health professionals direct assistance to working men and women to stop using smokeless tobacco, a known cause of oral, esophageal and pancreatic cancer," the researchers from the U.S. Centers for Disease Control and Prevention reported. The CDC called on employers to try to snuff out all forms of tobacco use. New smokeless tobacco products such as snus (finely ground moist snuff) and candy-flavored dissolvable tobacco, combined with increased marketing, might explain smokeless tobacco's steady use, the CDC authors said. However, snus and some other products weren't included in the questionnaire so it's possible smokeless tobacco use is underestimated, study author Dr. Jacek Mazurek, of the division of respiratory disease studies, and colleagues noted. Chewing tobacco and snuff aren't safe, research has shown. [...]

Charlotte Parker2014-06-06T10:47:15-07:00June, 2014|Oral Cancer News|

Study finds low public awareness of head and neck cancer

Source: www.sciencecodex.comAuthor: The JAMA Network Journals Bottom Line: Public awareness of head and neck cancer (HNC) is low, with few Americans knowing much about risk factors such as tobacco use and human papillomavirus (HPV). Author: Alexander L. Luryi, B.S., of the Yale University School of Medicine, New Haven, Conn. Background: HNC is the 10 th most common cancer in the United States. It is a potentially preventable disease with about 75 percent of cases caused by tobacco use. In recent years, HPV has been established as a risk factor for HNC. Increased public awareness of HNC and its risk factors could help improve outcomes. How the Study Was Conducted: An online study of 2,126 adults was conducted in 2013. Results: About 66 percent of the participants were "not very" or "not at all" knowledgeable about HNC. Smoking and chewing or spitting tobacco were identified by 54.5 percent and 32.7 percent of respondents as risk factors for mouth and throat cancer, respectively. Only 0.8 percent of respondents identified HPV as a risk factor. Discussion: "Awareness of HNC is low compared with other cancers, which is concerning given the importance of risk factor avoidance and modification, as well as early patient detection, as drivers of prevention and improved outcomes." *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2014-06-06T10:19:47-07:00June, 2014|Oral Cancer News|

Aerosmith’s Tom Hamilton begins to put post-cancer struggle behind him

Source:http://www.tv3.ieAuthor: Staff Aerosmith's Tom Hamilton admits the after effects of cancer treatment came back to ''bite'' him. The bass player, who was told his throat and tongue cancer had returned in 2011, had a difficult year last year after he pulled out of the band's tour of Australia and was replaced by David Hull due to health issues. He told digitaljournal.com: ''I had a couple of situations last year that I'm past. Sometimes the after effects of cancer treatment sort of come back to bite you later on down the road. That happened last year, but I'm feeling great now ... having an awesome time out here.'' The 62-year-old musician is now looking forward to touring the US with his Aerosmith band mates - Steven Tyler, Joe Perry, Brad Whitford and Joey Kramer - and he realises there might not be many more opportunities to play live which is why the band put their differences aside. He said: ''I think we all know that we're nearer the end than the beginning of this whole thing and nobody wants to miss anything - I certainly don't. ''I don't want to miss all the amazing stuff there is out in the world for us right now just because of an argument or because somebody is too burned out and they lash out or something. Everything is forgivable when you consider what's out there for us if we can keep it together...'' Asked if he had considered retiring from the group, he replied: ''Yeah, [...]

Charlotte Parker2014-06-05T11:45:36-07:00June, 2014|Oral Cancer News|

Aspen Dental and The Oral Cancer Foundation join together and conducted over 2,400 oral cancer screenings in April

Source: sacbee.comAuthor: Aspen Dental SYRACUSE, N.Y., May 29, 2014 -- Aspen Dental, one of the largest and fastest-growing networks of dental care providers in the U.S., conducted 2,420 oral cancer screenings at Aspen Dental locations during the month of April, resulting in a $12,100 donation to The Oral Cancer Foundation. The program, which included a $5 donation for each screening conducted, was run throughout the Aspen Dental network, which includes more than 450 practices across 27 states. Since 2010, Aspen Dental has donated more than $63,000 to The Oral Cancer Foundation. "Each year, oral cancer kills more people in the U.S. than other more widely known forms of cancer, including skin, lymphatic, thyroid, and cervical cancers," said Jamie O'Day, Director of Operations for The Oral Cancer Foundation. "The funds raised through Aspen Dental's oral cancer screening campaign in April are imperative to help OCF continue to sponsor research, provide patient support, education, and early detection initiatives which are all related to our mission. We are proud to be associated with an organization that makes oral cancer screenings a priority in their practices." According to The Oral Cancer Foundation, approximately 43,250 people in the US will be newly diagnosed with oral cancer in 2014. This is the eighth year in a row in which there has been an increase in the rate of occurrence of oral cancers, in 2007 there was a major jump of over 11% in that single year. "Unfortunately many patients are not familiar with the risk factors or symptoms that serve as warning signs of [...]

Charlotte Parker2014-06-05T11:35:53-07:00June, 2014|OCF In The News, Oral Cancer News|

New immunotherapy drug shows promise for advanced head/neck cancer

Source: www.drbicuspid.com Author: DrBicuspid staff A new immunotherapy treatment, MK3475, known as pembrolizumab, from Merck has proved effective in some patients with advanced head and neck, according to the early findings of a study presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The findings were presented by Tanguy Seiwert, MD, the associate director of the Head and Neck Cancer Program and assistant professor of medicine at the University of Chicago. In the phase IB study, a small number of patients with advanced head and neck cancer were treated with pembrolizumab, an anti-PD-1 antibody. The drug is part of an emerging class of medications that work by blocking the PD-1 protein, which is used by cancer cells to evade the body's immune system. When PD-L1 attaches to its receptor PD-1 on immune cells, tumors are able to hide from the immune system; drugs that target either PD-L1 or PD-1 inhibit this interaction. In the study presented at the ASCO meeting, 56 patients with advanced head and neck cancer whose tumors were assessed as positive for PD-L1 expression were evaluable for treatment response with pembrolizumab; 20 of the patients tested positive for human papillomavirus (HPV). The early findings showed a best overall response rate of 20%, with 29% of patients having stable disease. Similar overall response rates were observed in HPV-positive and HPV-negative patients. Tumor shrinkage was demonstrated in 51% of evaluable patients who had measurable disease with one postbaseline scan. The most common treatment-related adverse events [...]

Oral Cancer Foundation News Team - A2014-06-04T06:39:22-07:00June, 2014|Oral Cancer News|

Plasmonic nanobubbles can detect and kill only cancer cells

Source: www.azonano.com Author: staff The first preclinical study of a new Rice University-developed anti-cancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells — often by blowing them apart — without harming surrounding normal organs. The research, which is available online this week Nature Medicine, reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors. The work was conducted by researchers from Rice, the University of Texas MD Anderson Cancer Center and Northeastern University. “We address aggressive cancers that cannot be efficiently and safely treated today,” said Rice scientist Dmitri Lapotko, the study’s lead investigator. “Surgeons often cannot fully remove tumors that are intertwined with important organs. Chemotherapy and radiation are commonly used to treat the residual portions of these tumors, but some tumors become resistant to chemoradiation. Quadrapeutics steps up when standard treatments fail. At the same time, quadrapeutics complements current approaches instead of replacing them.” Lapotko said quadrapeutics differs from other developmental cancer treatments in that it radically amplifies the intracellular effect of drugs and radiation only in cancer cells. The quadrapeutic effects are achieved by mechanical events — tiny, remotely triggered nano-explosions called “plasmonic nanobubbles.” Plasmonic nanobubbles are non-stationary vapors that expand and burst inside cancer cells in nanoseconds in response to a short, low-energy laser pulse. Plasmonic nanobubbles act as a “mechanical drug” against cancer cells that cannot be surgically removed and are otherwise resistant to [...]

Oral Cancer Foundation News Team - A2014-06-03T06:07:14-07:00June, 2014|Oral Cancer News|

Low-dose IMRT may be safe for patients with HPV-positive head and neck cancer

Source: www.oncologypractice.com Author: Laura Nikolaides Lower-dose radiation therapy may be safe for some patients with human papillomavirus (HPV)-positive oropharyngeal cancer, decreasing the risk of often long-term side effects, such as trouble swallowing, dry mouth, loss of taste, neck stiffness, and thyroid problems, investigators reported at the annual meeting of the American Society of Clinical Oncology. Two-year overall survival and progression-free survival were 93% and 80%, respectively, among 62 patients with operable stage III/IVA HPV-positive oropharyngeal squamous carcinoma who received lower-dose intensity-modulated radiation therapy (IMRT) after clinical complete response to induction chemotherapy, reported Dr. Anthony Cmelak, professor of radiation oncology at Vanderbilt University, Nashville, Tenn., and medical director of the Vanderbilt-Ingram Cancer Center at Franklin. Overall, the phase II study enrolled 90 patients, median age 57 years, who all received induction chemotherapy with paclitaxel, cisplatin, and cetuximab. The response to induction chemotherapy determined IMRT dose. The 62 patients who had a complete clinical response received a reduced dose (54 Gy) of IMRT, and the rest of the patients received standard dose IMRT (70 Gy). All patients received standard cetuximab along with radiation. Two-year overall survival and progression-free survival for the higher-risk patients who received the standard dose of IMRT were 87% and 65% respectively. Among those patients receiving low-dose IMRT, survival was slightly higher for those with less than 10 pack-years of smoking and earlier-stage disease; in those patients 2-year progression-free and overall survival were 92% and 97%, respectively. However, Dr. Cmelak does not yet recommend modifying regimens for patients with [...]

Oral Cancer Foundation News Team - A2014-06-03T05:55:31-07:00June, 2014|Oral Cancer News|

Internal lymphedema causes swallow dysfunction among patients with head and neck cancer

Author: Bryant FurlowSource: oncologynurseadvisor.com CHICAGO, IL— Treatment-related dysphagia symptoms are likely caused by internal lymphedema among patients with head and neck cancer, according to research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting. “Internal lymphedema (correlated with subjective and objective measures of swallow dysfunction,” said lead author Leanne Kolnick Jackson, MD, at the Vanderbilt University Medical Center, Nashville, Tennessee. “Most of the time patients have silent aspiration, which is most dangerous. So if a patient ever says they have dysphagia, it warrants an exam” including imaging as well as endoscopy, Jackson said. External lymphedema is visible and recognizable, but internal lymphedema—which occurs in up to 90% of cases of external lymphedema—can go undetected, the coauthors noted. “External lymphedema is just the tip of the iceberg,” said senior author Barbara A. Murphy, MD, of Vanderbilt University Medical Center. “Only 10% of patients with lymphedema have only external lymphedema.” Secondary lymphedema and fibrosis are “ubiquitous and underreported” late effects among patients with head and neck cancers, Jackson reported. Using the Vanderbilt Head and Neck Symptom Survey (VHNSS) version 1.0, the researchers collected patient-reported swallow dysfunction among study participants undergoing treatment for head and neck cancer. They subsequently studied patients' swallow function and internal lymphedema, using endoscopic assessments, modified-barium videofluoroscopy, the Dysphagia Outcome and Severity Scale (DOSS), and National Outcomes Measurement System (NOMS). Endoscopy does not detect internal lymphedema well “for every site,” Jackson noted. “Some sites are not well evaluated by endoscopy.” At 18 months posttreatment, VHNSS swallow/nutrition scores [...]

Charlotte Parker2014-06-02T11:03:51-07:00June, 2014|Oral Cancer News|